Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report
Introduction: We discuss a case of massive hemoptysis in the setting of a direct-acting oral anticoagulant (DOAC) successfully managed with nebulized tranexamic acid (TXA). Case Report: Per the American College of Cardiology and the American Society of Hematology, it is recommended that significant...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eScholarship Publishing, University of California
2020-11-01
|
Series: | Clinical Practice and Cases in Emergency Medicine |
Online Access: | https://escholarship.org/uc/item/12n4q5j4 |
id |
doaj-4dcf462952a54f48ac8bb5f431770d2e |
---|---|
record_format |
Article |
spelling |
doaj-4dcf462952a54f48ac8bb5f431770d2e2020-11-25T04:10:43ZengeScholarship Publishing, University of CaliforniaClinical Practice and Cases in Emergency Medicine2474-252X2020-11-014410.5811/cpcem.2020.7.48525cpcem-04-572Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case ReportJacqueline M. Dempsey0Mandy Jones1Jonathan Bronner2Connor Greer3Gavin T. Howington4University of Kentucky HealthCare, Department of Pharmacy Services, Lexington, KentuckyUniversity of Kentucky, Department of Pharmacy Practice and Science, Lexington, KentuckyUniversity of Kentucky HealthCare, Department of Emergency Medicine, Lexington, KentuckyUniversity of Kentucky HealthCare, Department of Emergency Medicine, Lexington, KentuckyUniversity of Kentucky HealthCare, Department of Pharmacy Services, Lexington, KentuckyIntroduction: We discuss a case of massive hemoptysis in the setting of a direct-acting oral anticoagulant (DOAC) successfully managed with nebulized tranexamic acid (TXA). Case Report: Per the American College of Cardiology and the American Society of Hematology, it is recommended that significant bleeding associated with a DOAC be treated with either 4-factor prothrombin complex concentrate or andexanet alfa. However, our patient was at high risk for thrombotic complications given a recent pulmonary embolism. Conclusion: We demonstrate that it is reasonable to trial nebulized TXA given its low cost, ease of administration, and safety profile. Additionally, this report discusses a unique dosing strategy and a previously unreported complication associated with nebulization of undiluted TXA.https://escholarship.org/uc/item/12n4q5j4 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jacqueline M. Dempsey Mandy Jones Jonathan Bronner Connor Greer Gavin T. Howington |
spellingShingle |
Jacqueline M. Dempsey Mandy Jones Jonathan Bronner Connor Greer Gavin T. Howington Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report Clinical Practice and Cases in Emergency Medicine |
author_facet |
Jacqueline M. Dempsey Mandy Jones Jonathan Bronner Connor Greer Gavin T. Howington |
author_sort |
Jacqueline M. Dempsey |
title |
Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report |
title_short |
Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report |
title_full |
Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report |
title_fullStr |
Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report |
title_full_unstemmed |
Inhaled Tranexamic Acid for Massive Hemoptysis in the Setting of Oral Anticoagulation: A Case Report |
title_sort |
inhaled tranexamic acid for massive hemoptysis in the setting of oral anticoagulation: a case report |
publisher |
eScholarship Publishing, University of California |
series |
Clinical Practice and Cases in Emergency Medicine |
issn |
2474-252X |
publishDate |
2020-11-01 |
description |
Introduction: We discuss a case of massive hemoptysis in the setting of a direct-acting oral anticoagulant (DOAC) successfully managed with nebulized tranexamic acid (TXA). Case Report: Per the American College of Cardiology and the American Society of Hematology, it is recommended that significant bleeding associated with a DOAC be treated with either 4-factor prothrombin complex concentrate or andexanet alfa. However, our patient was at high risk for thrombotic complications given a recent pulmonary embolism. Conclusion: We demonstrate that it is reasonable to trial nebulized TXA given its low cost, ease of administration, and safety profile. Additionally, this report discusses a unique dosing strategy and a previously unreported complication associated with nebulization of undiluted TXA. |
url |
https://escholarship.org/uc/item/12n4q5j4 |
work_keys_str_mv |
AT jacquelinemdempsey inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport AT mandyjones inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport AT jonathanbronner inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport AT connorgreer inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport AT gavinthowington inhaledtranexamicacidformassivehemoptysisinthesettingoforalanticoagulationacasereport |
_version_ |
1724419453933846528 |